Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

26 recruitingLast updated: June 17, 2026

There are 26 actively recruiting head and neck squamous cell carcinoma (hnscc) clinical trials across 21 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Los Angeles, California, United States, Boston, Massachusetts, United States, Pittsburgh, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Head and Neck Squamous Cell Carcinoma (HNSCC) Trials at a Glance

26 actively recruiting trials for head and neck squamous cell carcinoma (hnscc) are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 14 trials, with the heaviest enrollment activity in Los Angeles, Boston, and Pittsburgh. Lead sponsors running head and neck squamous cell carcinoma (hnscc) studies include Sun Yat-sen University, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., and West China Hospital.

Browse head and neck squamous cell carcinoma (hnscc) trials by phase

Treatments under study

About Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

Looking for clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head and Neck Squamous Cell Carcinoma (HNSCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 26 trials

Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737
Recruiting
Phase 1

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting
Phase 2

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled10 locationsNCT06769698
Recruiting
Phase 2

[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma (HNSCC)
John O. Prior20 enrolled1 locationNCT06794372
Recruiting
Not Applicable

Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University50 enrolled1 locationNCT06630780
Recruiting
Phase 1

Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy

Head and Neck Squamous Cell Carcinoma (HNSCC)
West China Hospital6 enrolled1 locationNCT07545967
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

Window of Opportunity in Preserving Laryngeal Function Trial

Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Matthew Spector87 enrolled1 locationNCT07423078
Recruiting
Phase 2

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute32 enrolled2 locationsNCT07465276
Recruiting
Phase 1

GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study

Head and Neck Squamous Cell Carcinoma (HNSCC)
West China Hospital9 enrolled1 locationNCT07457281
Recruiting
Phase 1

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Colorectal, CancerEsophageal CancerGastric Cancer+6 more
Sutro Biopharma, Inc.200 enrolled6 locationsNCT07227168
Recruiting
Phase 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)
Dan Zandberg80 enrolled1 locationNCT04080804
Recruiting
Not Applicable

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

Head and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer
Wake Forest University Health Sciences75 enrolled3 locationsNCT06607406
Recruiting
Not Applicable

Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma (HNSCC)
Centre Henri Becquerel192 enrolled2 locationsNCT07190755
Recruiting
Phase 1Phase 2

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1Phase 2

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Esophageal CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+22 more
VM Oncology, LLC242 enrolled15 locationsNCT03556228